Thinking
laterally
about CAR-T
Our mission is to develop CAR-T therapies to improve treatment outcomes and save the lives of patients with refractory cancers.
Join us at Jefferies Healthcare Conference
November 16 to 19, 2021
Location: London, UK
The 2021 conference will again feature leading public and private companies from the pharmaceuticals, biotechnology, medical technology, and healthcare services sectors from the Americas, Europe, Middle East, Africa, Asia, and Australia.
Jefferies London Healthcare Conference 2021 will be held both in-person in London and virtually, featuring live and on-demand presentations, fireside chats, panels and small group meetings to connect companies and investors.
Our Science
CAR T-cell therapy is a revolutionary technology in which immune cells, called T-cells, are reprogrammed so they can recognise and destroy cancer cells.
Parallel CAR T-Cell Platform
Founded to translate 20 years of pioneering CAR-T research led by Dr John Maher at King's College London (King's), Leucid Bio has developed a proprietary portfolio based upon Dr Maher’s novel approach, in which the CAR structure has been redesigned to recapitulate the lateral distribution of signalling domains as observed in natural immune receptors. The technology gives properties to the CAR-Ts that enable them to consistently outperform previous generations of CAR-T therapies in pre-clinical studies; enhancing T-cell potency and generating a persistent long-term response with reduced toxicity.
.png)
T4 Immunotherapy
Leucid Bio’s T4 Immunotherapy is a pan-ErbB targeted autologous CAR T-cell product for patients with otherwise untreatable head and neck cancer. It is currently in Phase I, with 18 patients treated to date, of whom 10 have achieved disease stabilisation.
Novel Manufacturing Platforms
Leucid Bio has developed an improved, more rapid and scalable manufacturing process that relies on a simple blood draw.
_2.jpg)